Get started
Author

Sanjeev Forsyth

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
2022 · Justin M Watts, Maria R Baer, et al. · The Lancet Haematology · 124
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1 -mutant glioma: A multicenter, open-label, phase Ib/II trial
2022 · Macarena I de la Fuente, Howard Colman, et al. · Neuro-Oncology · 87
PDF
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease
2022 · Patricia Schroeder, Keertik Fulzele, et al. · Journal of Pharmacology and Experimental Therapeutics · 52
PDF
Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease
2024 · Santosh L. Saraf, Robert Hagar, et al. · Blood Advances · 36
PDF
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial
2022 · Sanjeev Forsyth, Patricia Schroeder, et al. · Clinical Pharmacology in Drug Development · 36
PDF
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study
2019 · Justin M. Watts, Maria R. Baer, et al. · Blood · 27
A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.
2020 · Macarena Ines De La Fuente, Howard Colman, et al. · Journal of Clinical Oncology · 18
Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine
2019 · Jorge E. Cortes, Eunice S. Wang, et al. · Blood · 18
FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease
2020 · R. Clark Brown, Kimberly Cruz, et al. · Blood · 16
A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent.
2020 · Robin Lewis Jones, Teresa Macarulla, et al. · Journal of Clinical Oncology · 10
Activation of Pyruvate Kinase-R with Etavopivat (FT-4202) Is Well Tolerated, Improves Anemia, and Decreases Intravascular Hemolysis in Patients with Sickle Cell Disease Treated for up to 12 Weeks
2021 · R. Clark Clark Brown, Santosh L. Saraf, et al. · Blood · 9
Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects
2019 · Theodosia A. Kalfa, Frans A Kuypers, et al. · Blood · 9
Ps1051 Ft-2102, an Idh1 M Inhibitor, Induces Mutation Clearance in Patients With Acute Myeloid Leukemia (aml) or Myelodysplastic Syndrome (mds) Treated in Phase 1 Dose Escalation and Expansion Study
2019 · S. De Botton, J. Watts, et al. · HemaSphere · 6
Actr-52. Phase 1 Study of Ft-2102, an Inhibitor of Mutant Idh1, in Patients With Relapsed/refractory Idh1 Mutant Gliomas: Preliminary Safety and Clinical Activity
2019 · Macarena I De la Fuente, Howard Colman, et al. · Neuro-Oncology · 3
Scidot-42. Ft-2102 – a Potent and Selective Brain Penetrant Inhibitor of Mutant Isocitrate Dehydrogenase
2019 · Maria Ribadeneira, Sylvie Guichard, et al. · Neuro-Oncology · 2
Tu1211 IW-9179, a Phosphopeptide Designed to Target the Upper Gastrointestinal Tract, Is More Potent at Acidic pH and Is Rapidly Metabolized In Vitro in Rodent Intestinal Fluid
2015 · Marco Kessler, Robert Solinga, et al. · Gastroenterology · 2
Pf269 Ft-2102, an Idh1 M Inhibitor, Combined With Azacitidine in Patients With Acute Myeloid Leukemia (aml) or Myelodysplastic Syndrome (mds): Results From a Phase 1 Study
2019 · J.E. Cortes, J. Watts, et al. · HemaSphere
Works count: 17
Citation count: 455
H-index: 10
I10-index: 10
Year
Topic
Type